Cancer drug combo tested in kids, but study stopped early
NCT ID NCT04544995
First seen Jan 21, 2026 · Last updated Apr 30, 2026 · Updated 14 times
Summary
This early-phase study aimed to find a safe dose of two drugs (niraparib and dostarlimab) given together to children and teens (ages 6 months to 18 years) with solid tumors that had come back or not responded to treatment. The goal was to see if the combination could shrink tumors or slow their growth. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Birmingham, B4 6NH, United Kingdom
-
GSK Investigational Site
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.